Drug intelligence / Profile preview

BI 3804379

Development stage: Phase 1
Lead developer: Boehringer
Administration: Subcutaneous

Overview

BI 3804379 is an investigational drug developed by Boehringer Ingelheim. It is a new molecular entity currently in early clinical development, with its highest phase being Phase 1 as of late 2024. The drug's mechanism of action and therapeutic target have not been disclosed publicly. Initial studies are focused on evaluating the safety, tolerability, and pharmacokinetics of single and multiple rising subcutaneous doses in healthy volunteers. The primary indication for BI 3804379 remains undisclosed[1][2][3][4][6].

Beyond the preview

Go deeper on BI 3804379.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 3804379.

Explore the full profile